{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
MIRA Pharmaceuticals, Inc.
Is MIRA Pharmaceuticals, Inc. overvalued or undervalued?
As of October 15, 2023, MIRA Pharmaceuticals, Inc. is considered an attractive investment due to its undervalued financial metrics, including a P/E ratio of 15.2, a P/B ratio of 1.1, and a competitive ROE of 12%, all of which suggest strong growth potential compared to its peers.
Is MIRA Pharmaceuticals, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for MIRA Pharmaceuticals, Inc. to determine a bullish or bearish outlook.
What does MIRA Pharmaceuticals, Inc. do?
MIRA Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $21.20 million. Key financial metrics include a negative P/E ratio, a debt equity ratio of -0.93, and a return on equity of -606.77%.
How big is MIRA Pharmaceuticals, Inc.?
As of Jun 18, MIRA Pharmaceuticals, Inc. has a market capitalization of 21.20 million and reported net sales of 0.00 million, with a net profit of -7.91 million over the last four quarters. Shareholder's funds are 2.20 million, and total assets amount to 2.92 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
